FEIBA NF 3250 UNIT
ANTI-INHIBITOR COAGULANT COMPLEX : 3250 UNIT · DIN 02353903 · TAKEDA CANADA INC
Health Canada status: MARKETED
What is FEIBA NF?
FEIBA NF 3250 UNIT contains ANTI-INHIBITOR COAGULANT COMPLEX : 3250 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02353903, held by TAKEDA CANADA INC, supplied as POWDER FOR SOLUTION ; KIT for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FEIBA NF used for?
FEIBA NF (Anti - Inhibitor Coagulant Complex) is indicated for: Use in Hemophilia A and B patients with inhibitors for: Control of spontaneous bleeding episodes; Surgical interventions; Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children older than 6 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02353903 |
|---|---|
| Brand name | FEIBA NF |
| Generic / active ingredient | ANTI-INHIBITOR COAGULANT COMPLEX : 3250 UNIT |
| Manufacturer | TAKEDA CANADA INC |
| Strength | 3250 UNIT |
| Dosage form | POWDER FOR SOLUTION ; KIT |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B02BD03 FACTOR VIII INHIBITOR BYPASSING ACTIVITY |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jul-2021 |
| Original market date | 2011-04-04 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Freeze - Dried Powder with Solvent for Intravenous Injection or Infusion, 350 - 650 Units per 10mL, 700 - 1300 Units per 20mL, 1750 - 3250 Units per 50mL
What can be used instead?
Other Canadian products sharing ATC code B02BD03 FACTOR VIII INHIBITOR BYPASSING ACTIVITY. 2 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FEIBA NF | 1300 UNIT | KIT ; POWDER FOR SOLUTION | TAKEDA CANADA INC | MARKETED | DIN 02202581 |
| FEIBA NF | 650 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | CANCELLED PRE MARKET | DIN 02480549 |
| FEIBA NF | 650 UNIT | POWDER FOR SOLUTION ; KIT | TAKEDA CANADA INC | APPROVED | DIN 02489600 |
| FEIBA VH IMMUNO ANTI INHIBITOR | POWDER FOR SOLUTION | OSTERREICHISCHES INSTITUT FUR HAEMODERIVATE GES M.B.H. | CANCELLED POST MARKET | DIN 00609137 |
Who else supplies FACTOR VIII INHIBITOR BYPASSING ACTIVITY worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FACTOR VIII INHIBITOR BYPASSING ACTIVITY appears in 714 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.